美国消化肿瘤专家:乔尔.伦道夫.赫克特(Joel Randolph Hecht)

2017-09-20 13:45 ·

乔尔.伦道夫.赫克特(Joel Randolph Hecht)博士专精于消化道恶性肿瘤,在该领域的临床诊疗和研究成果享誉国际。他在多个医学权威刊物杂志上发表了大量的学术研究报告,内容涉及胃肠道恶性肿瘤的分子生物学(molecular biology)、早期检测(early detection)和治疗(treatment)等方面。

在线轻松预约,无需出国即可与美国医生“面对面”视频交流,获取权威专业的第二诊疗意见和方案!登录好医友官网查询更多美国医生信息(咨询热线4008860922)

 

【执业认证】

美国内科医学委员会——内科(Internal Medicine)医师资格认证

美国内科医学委员会——内科肿瘤(Medical Oncology)医师资格认证

美国内科医学委员会——肠胃专科(Gastroenterology)医师资格认证

 

【职务职称】

  加州大学洛杉矶分校罗纳德里根医学中心(Ronald Reagan UCLA Medical Center) 肠胃肿瘤专科主任

  加州大学洛杉矶分校大卫格芬医学院(David Geffen School of Medicine at UCLA) 临床医学教授

  加州大学洛杉矶分校(UCLA)胃肠道肿瘤项目 主任

  约恩逊综合癌症中心信号传导与治疗程序计划(Johnson Comprehensive Cancer Center Signal Transduction and Therapeutics Program)成员

  美国临床肿瘤学会(American Society of Clinical Oncology – ASCO)资深研究员

 

【医疗专长】

乔尔.伦道夫.赫克特(Joel Randolph Hecht)博士专精于消化道恶性肿瘤,在该领域的临床诊疗和研究成果享誉国际。他在多个医学权威刊物杂志上发表了大量的学术研究报告,内容涉及胃肠道恶性肿瘤的分子生物学(molecular biology)、早期检测(early detection)和治疗(treatment)等方面。赫克特博士不仅具备丰富的科研经历和逾30年的专科临床经验,同时也带领一支卓越的科研团队,负责新分子小型试验和大型国际随机试验项目,目前他正在进行的研究包括临床前期的生物诊疗模型,尖端造影技术,肿瘤基因治疗载体和酪氨酸激酶抑制剂的早期研究,以及主导新药第二期、三期的临床试验等。

 

【荣誉和奖项】

  入选医学卫生领域名人录(Whos Who in Medicine and Healthcare)- Marquis Whos Who

  入选SuperDoctors.com评选的“超级医生(Super Doctor)”

 

【教育背景】

  医学教育:1984年毕业于东弗吉尼亚医学院(Eastern Virginia Medical School),获得医学博士学位;

  实习/住院医培训:在西北大学费恩柏格医学院(Northwestern University, Medical School),接受内科(Internal Medicine)实习和住院医培训;

  专科培训:在加州大学洛杉矶分校医学院(UCLA, School of Medicine)完成内科肿瘤学(Medical Oncology)和内科/胃肠病学(Medicine/Gastroenterology)专科临床培训。

 

【合作医院】

加州大学洛杉矶分校罗纳德.里根医疗中心(Ronald Reagan UCLA Medical Center)

圣塔莫尼卡加州大学洛杉矶分校医疗中心(UCLA Medical Center, Santa Monica)

圣塔莫尼卡普罗维登斯圣约翰健康中心(Providence Saint John's Health Center)

 

【临床重点】

 

胃癌、小肠癌、食道癌、结直肠癌、胰腺癌、肝癌、胆管癌等消化道恶性肿瘤的预防、筛查与诊疗。其他临床关注点:血液肿瘤、神经内分泌肿瘤、遗传学等。

 

【出版物摘选】

  Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB.JAMA Oncol. 2017 Jun 1

  Most intended management changes after 68Ga-DOTATATE PET/CT are implemented.Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney A, Hendifar A, Pisegna J, Hecht JR, Wolin E, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach M, Herrmann K.J Nucl Med. 2017 May 4

  THREE DIAGNOSES ON ONE GALLIUM-68 DOTATATE SCAN.Yu R, Quon A, Hecht JR.Endocr Pract. 2017 Mar 23

  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D.J Clin Oncol. 2016 Feb 10

  SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY.Clin Colorectal Cancer. 2015 Jun;14

  Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.Ward P, Hecht JR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Naeim A.J Geriatr Oncol. 2014 Oct 1

  A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR.J Geriatr Oncol. 2013 Oct

  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B.Nature. 2012 Jun 28

  Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR.Br J Cancer. 2011 Sep 6

更多出版物查询:https://www.ncbi.nlm.nih.gov/pubmed

【媒体报道】

   

UCLA's Jonsson Comprehensive Cancer Center scientist Dr. J. Randolph Hecht did a satellite radio tour to promote awareness as November is Pancreatic Cancer Awareness Month. Here, he speaks on Knoxville, Tenn., radio station WCXZ AM 74. (赫克特博士 11月胰腺癌月宣传)

 

附图: